tesa Labtec GmbH

  • Booth: 1342

tesa Labtec is the innovative pharma business of the tesa SE / Beiersdorf AG group of companies. We offer contract development and manufacturing of transdermal and topical patches as well as oral soluble and buccal films. Despite current belief, our technologies are not limited to small molecules only; we are able to deliver you precious biomolecules, such as vaccines, allergens, and peptides as well. We offer a one-stop shopping experience for our customers. From early development to the manufacturing of products for the market. Our two cGMP sites in Germany are also sucessfully US FDA inspected.


  • Mucofilm®
    Our coated, ultra-thin Mucofilm® allows a persistent adhesion to the mucosa that enables transmucosal drug delivery. Great advantages for patients and pharmaceutical companies result in an excellent opportunity for drug delivery....

  • Buccal delivery of drugs offers several advantages compared to tablets, for example. The drug becomes systemically available by direct uptake through the mucosa. The result is an almost immediate onset of action and prompt relief. Less metabolites due to reduced first-pass effect. This allows for a marked reduction of the applied dose and causes fewer side effects. Our Mucofilm® technology opens up completely new possibilities for molecules with low bioavailability.

    tesa Labtec is able to design buccal films with single or multiple layers in varying thicknesses that can incorporate different actives. By specifically modifying the design of the carrier, the drug can be unidirectionally released to the buccal mucosa, both for local or systemic uptake, or into the oral cavity for local action. tesa Labtec’s buccal systems exhibit mucoadhesive properties upon contact with saliva, resulting in secure adhesion to the application site. Mucofilm® can be designed to either dissolve or to remain in its original form.
  • Transfilm®
    tesa Labtec is specialised in the development of different types of patches. Using our Transfilm® technology we can develop topical, transdermal as well as buccal patches....

  • A transdermal patch or transdermal system (TDS) is a medicated adhesive patch that is placed on the skin to deliver a specific dose of drug through the skin and into the bloodstream.

    The fact that transdermal patches can provide a controlled release of medication from 24 hours up to seven days gives it a major advantage over other types of drug delivery, such as oral or other types of topical administration (for example, gels or creams).

    The delivery of a drug via a transdermal route of application offers the best of oral and intravenous administration. Avoidance of the first-pass effect leads to better bioavailability and may result in fewer side effects. Consistent and controlled drug delivery can minimize or avoid periods of under- and overdosing. Transdermal patches deliver drugs over a longer period of time, thus allowing for reduced dosing frequency. A transdermal patch is administered by the patients themselves and administration is stopped by removal of the patch. Contrary to intravenous drips or infusion pumps, patient activity is not restricted. These numerous benefits lead to significantly improved patient compliance and as a consequence transdermal patches can offer a critical edge to new and established drugs in competitive markets.
  • Rapidfilm®
    The ultra thin and small films offer various advantages for patients and care givers and can contain many different active ingredients. Our Rapidfilm® can be applied in many therapeutic indications and states the most convenient oral dosage form....

  • Our Rapidfilm® is an innovative oral dosage form that offers strong advantages to patients and combines the convenience of a liquid with the stability and dosing accuracy of a tablet. We offer this technology accompanied by our development and manufacture expertise to our customers.

    A Rapidfilm® is a very thin film which is applied in the mouth. It is based on water soluble polymers. Our films typically have a size of 3-9 cm2 and provide a thickness between 50 and 500 µm. The design can vary from single to multi layer systems. The main advantages of a Rapidfilm® are:

    • Easy application - no swallowing difficulties and therefore high acceptance by elderly and children
    • No beverages necessary for intake
    • The film cannot be spat out
    • Risk of Aspiration reduced
    • Ideal „take-away medicine“
    • Area proportional dosage form allowing for numerous different doses from one base laminate
    The orodispersible Rapidfilm® works like a conventional or orodispersible tablet. The film is placed on the tongue and dissolves within a few seconds. The active ingredient is swallowed together with the saliva and takes the same route as a tablet via the liver where the drug is metabolized.